1Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol, 2003, 3:521 - 533.
2Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol, 2002, 20 : 495 - 549.
3Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun, 2000, 68:1542 - 1548.
4Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmunity Rev, 2004, 3:390 - 400.
5Colie B, Camilleri M, Bharucha AE, et al. Colonic motility in chronic ulcerative pmctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther,2001, 15:653 - 663.
6Sher ME, Bank S, Greenberg R, et al. The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease. Infamm Bowel Dis, 1999, 5:73 - 78.
7Evans JM, McMahon AD, Murray FE, et al. Non-steroidal antiinflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut,1997, 40:619 - 622.
8Qiu BS, Vallance BA,Blennerhassettk PA, et al. The role of CD4^+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Nat Med, 1999, 5:1178 - 1182.
9Maunder RG, Lancee WJ, Greenberg GR, et al. Insecure attachment in a subgroup with ulcerative colitis defined by ANCA status. Dig Dis Sci, 2000, 45:2127 - 2132.
10Andersson RE, Olaison G, Tysk C, et al. Appendectomy and protection against ulcerative colitis. N Engl J Med,2001, 344:808 - 814.
